Glaxosmithkline symptoms and conditions

Yes it does affect your kidneys, you are on a really high dose too, I think the maximum is meant to be 400mg a day. For everyone that says their doctors are telling them that their symptoms are not side effects from Lamictal, all you have to do is take in the information leaflet (the tiny folded up paper one) that comes in the box with the pills. Some companies have less side effects listed in their leaflet which is odd (GlaxoSmithKline hardly lists any) But APS lists involuntary movement of the eyes. There was another brand I used to be on that had a huge long list of side effects but I can't think what it was. If you search online you should be able to find a good list.

I must admit I am very surprised by all of the side effects of Advair. I have been taking Advair 250 for years and have NEVER had any problems. I'm 28, healthy, thin, and happy. I exercise several times a week. ALL drugs have side effects. I don't think it's fair for anyone to say "don't take Advair, it's a horrible drug" because it works for some of us. I was taking Flovent before but it didn't work for me. I needed a rescue inhaler several times a week. Since I've been taking Advair I don't even fill my prescription for my rescue inhaler! All drugs have side effects, but they don't effect all people!

More evidence of what I have been saying about genetics and the leukotriene pathway that Singulair blocks. FLAP's as mentioned below are actually the same era as Singulair (late 90's)--many scientists were looking at this pathway.

The genetic component is so "in your face" every where that I am quite appalled that Merck has not at least addressed that issue by now.

Monday, June 02, 2008
Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
Rated Not yet rated
Rate This Recommend Email this Story | Respond to Editor | Print

SEND ComtexDigg It StumbleUpon Newsvine Reddit SAN DIEGO, Jun 02, 2008 (PR Newswire Europe via COMTEX) ----GSK exercises option for AM803, a FLAP inhibitor which recently completed phase I studies

Amira Pharmaceuticals today announced that under the terms of a worldwide exclusive agreement entered into in Feb 2008, GlaxoSmithKline (GSK: 43.65, -0.88, -1.97%) will exercise its right to a second FLAP compound, AM803. Under the original agreement, GSK has rights to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein) inhibitors for the treatment of respiratory and cardiovascular disease. The decision to develop AM803 follows the successful completion of a phase I study by Amira, which demonstrated its potential as a once-daily FLAP inhibitor.

"Exercise of this option by GSK caps a productive first few months during which Amira has hit a number of near term milestones. Hitting these milestones early has not only further strengthened our relations with GSK, but has resulted in meaningful economic benefit to Amira," said Hari Kumar, Chief Business Officer, Amira. "The project has started extremely well and we are very pleased at the commitment of GSK and the progression of development."

About FLAP Inhibitors

FLAP (5-Lipoxygenase Activating Protein) is a key component early in the leukotriene pathway, a complex signaling process that exerts control over biological processes, such as inflammation and immunity. Excessive production of leukotrienes exacerbates inflammatory diseases, such as asthma; the FLAP gene has also been linked to a significant increase in the risk of myocardial infarction and stroke. AM103 and AM803 bind to FLAP, inhibiting the synthesis of leukotrienes that cause inflammation.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the eicosanoid pathway.

The company combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R: 73.05, -0.38, -0.51%). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit http://www.amirapharm.com.

Web site: http://www.amirapharm.com

I have been on Advair for the past three years after a severe asthma attack on Oct 2005....what a mistake..I got all the side effects possible...really! Rash, arrhythmia, tachycardia, eye problems, runny nose, shakines, depression, anxiety, sleeping problems, nausea, muscle cramps or muscle spasms, hoarseness or voice changes, sinus infections, abdominal pain, dizziness, etc, etc and it is gatting worse! I am on 100/50 once...every two days! I could not stand all of this anymore- Does anyone know about some other less dangerous medication (Albuterol gives me the worse arrhythmia) Is it sensible to note that Advair and another dangerous medication; Paxil are from the same maker: glaxosmithkline pharmaceuticals? No wonder! Any input/help will be most welcome-A very worry French guy in San Francisco-

I'm 58 with COPD and the Dr. put me on Advair for breathing. I have been having severe join pain the last two weeks and believe it may be from the rx. also, have reccurring pneumonia, thrush, and sleep disturbances. Sound familiar? let me know if you have the joint pain.

I have been taking advair for over a year now. I would have not minded a bit the hoarseness, but the trembling, constant irratation, the worsening of my asthma ( yes, due to Advair), the weird palpitations, etc, are not what I expected from Advair. I am not surprised now when I just read it is a product of GlaxoSmithKline, famous for its disastrous Paxil and its subsequent scandals.
Fight GlaxoSmithKline.... The Secrets of Seroxat, BBC Panorama investigation, including....ADVAIR!!